Schonfeld Strategic Advisors LLC Fibrogen Inc Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $8,633 - $22,892	9,700 Added 24.56%	49,200 $43,000
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $28,835 - $107,835	39,500 New	39,500 $92,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $137,505 - $1.14 Million	55,223 New	55,223 $149,000
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $565,200 - $723,853	49,579 New	49,579 $645,000
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $516,264 - $991,939	-27,801 Reduced 69.85%	12,000 $320,000
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $1.23 Million - $2.22 Million	39,801 New	39,801 $1.38 Million
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $3.05 Million - $4.27 Million	-71,300 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $2.71 Million - $4.29 Million	71,300 New	71,300 $3.3 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.